Limited options, high costs, and a lack of novel ideas have long hindered the treatment of rare genetic disorders. Existing therapies may manage symptoms for millions of patients worldwide, but often fall short regarding long-lasting changes. Lingyi Biotech is a clinical-stage biotechnology company that's taking a different approach.